Medications used to treat skin conditions include topical and oral drugs
August 26, 2019
Medications for pain General and laparoscopic surgeon
August 26, 2019
FDA Approved Drugs for Rheumatology
Drugs Approved in 2019
Cimzia (certolizumab pegol); UCB; For the treatment of non-radiographic axial spondyloarthritis, Approved March 2019
Rinvoq (upadacitinib); AbbVie; For the treatment of rheumatoid arthritis, Approved August 2019
Drugs Approved in 2018
Olumiant (baricitinib); Eli Lilly; For the treatment of moderate to severe rheumatoid arthritis with inadequete response to TNF antagonist therapies, Approved May 2018
Drugs Approved in 2017
Duzallo (lesinurad and allopurinol) ; Ardea Biosciences; For the treatment of hyperuricemia associated with gout , Approved August 2017
Kevzara (sarilumab); Sanofi ; For the treatment of active rheumatoid arthritis, Approved May 2017
Zilretta (triamcinolone acetonide extended-release injectable suspension); Flexion Therapeutics; For the treatment of osteoarthritis knee pain, Approved October 2017
Drugs Approved in 2016
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016
Drugs Approved in 2014
Otezla (apremilast); Celgene; For the treatment of adults with active psoriatic arthritis, Approved March 2014
Drugs Approved in 2013
Actemra (ocilizumab); Genentech; For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013
Cimzia (certolizumab pegol); UCB; For the treatment of active psoriatic arthritis, Approved September 2013
Cimzia (certolizumab pegol); UCB; For the treatment of active ankylosing spondylitis , Approved October 2013
Ilaris (canakinumab); Novartis; For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013
Drugs Approved in 2012
Rayos (prednisone) delayed-release tablets; Horizon Pharma; For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions, Approved July of 2012
Stendra (avanafil); Vivus; For the treatment of erectile dysfunction, Approved April 2012
Xeljanz (tofacitinib); Pfizer; For the treatment of moderately to severely active rheumatoid arthritis, Approved November 2012
Drugs Approved in 2011
Actemra (tocilizumab); Genentech; For the treatment of systemic juvenile idiopathic arthritis, Approved April 2011
Duexis (ibuprofen and famotidine); Horizon Pharma; For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011
Drugs Approved in 2010
Actemra (tocilizumab); Genentech; For the treatment of rheumatoid arthritis, Approved January 2010
Krystexxa (pegloticase); Savient Pharma; For the treatment of chronic gout (hyperuricemia), Approved September 2010
Vimovo (naproxen + esomeprazole); AstraZeneca; For the treatment of arthritis in patients at risk for NSAID-associated ulcers, Approved April 2010
Drugs Approved in 2009
Cimzia (certolizumab pegol); UCB; For the treatment of rheumatoid arthritis, Approved May of 2009
Colcrys (colchicine); Mutual Pharmaceuticals; For gout flares and familial Mediterranean fever, Approved October 2009
Pennsaid (diclofenac sodium topical solution); Nuvo Research; For the treatment of osteoarthritis of the knee, Approved November 2009
Simponi (golimumab); Centocor Ortho Biotech; For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Approved April 2009
Stelara (ustekinumab); Janssen Biotech; For the treatment of plaque psoriasis, psoriatic arthritis and Crohn’s disease, Approved September 2009
Uloric (febuxostat); Takeda; For the treatment of chronic hyperuricemia in patients with gout, Approved February 2009
Drugs Approved in 2008
Orencia (abatacept); Bristol-Myers Squibb; For the treatment of Juvenile Idiopathic Arthritis, Approved April 2008
Drugs Approved in 2006
Elaprase (idursulfase); Shire Pharmaceuticals; For the treatmenr of mucopolysaccharidosis II (Hunter Syndrome), Approved July 2006
Rituxan (rituximab); Biogen IDEC, Genentech; For the treatment of moderately-to severely-active rheumatoid arthritis, Approved February 2006
Drugs Approved in 2005
Orencia (abatacept); Bristol-Myers Squibb; For the Treatment of Rheumatoid Arthritis, Approved December 2005
Drugs Approved in 2004
Vioxx (rofecoxib); Merck; For the treatment of rheumatoid arthritis, Approved April 2002 — UPDATED: WITHDRAWN OCTOBER 2004
Drugs Approved in 2002
Enbrel (etanercept); Immunex; For the treatment of psoriatic arthritis, Approved January 2002
Humira (adalimumab); Abbott Laboratories; For the treatment of moderately to severely active rheumatoid arthritis, Approved December 2002
Remicade (infliximab); Centocor Ortho Biotech; Intravenous infusion for the treatment of rheumatoid arthritis, Approved February 2002
Drugs Approved in 2001
Bextra; Pharmacia, Pfizer; Oral tablet for the treatment of osteoarthritis, rheumatoid arthritis and menstrual pain, Approved November 2001
Kineret; Amgen; Injectable therapy for the treatment of rheumatoid arthritis, Approved November 2001
Remicade (infliximab); Centocor Ortho Biotech; For inhibiting the progression of structural damage in patients with rheumatoid arthritis, Approved January 2001
Supartz; Smith & Nephew Orthopaedics; Joint fluid therapy for treatment of osteoarthritis in the knee, Approved January 2001
Drugs Approved in 2000
Mobic (meloxicam) Tablets; Boehringer Ingelheim; For relief of the signs and symptoms of osteoarthritis, Approved April 2000
Vivelle (estradiol transdermal system); Novartis; For the prevention of postmenopausal osteoporosis, Approved August 2000
Drugs Approved in 1999
Lodine XL (etodolac); Wyeth; Treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis, Approved May 1999
Drugs Approved in 1998
Arava; Hoechst Marion Roussel; Treatment for Rheumatoid Arthritis, Approved September 1998
Lodine XL (etodolac); Wyeth; Treatment for arthritis, Approved February 1998
Salagen Tablets; MGI Pharma; Treatment for Sjogren’s Syndrome, Approved February 1998
Drugs Approved in 1997
Arthrotec; Searle; Treatment for arthritis, Approved December 1997
Etodolac; Royce Laboratories; Generic equivalent of Lodine, Approved December 1997
Etodolac; Royce Laboratories; Generic equivalent of Lodine, Approved April 1997
Ketoprofen; Schein Pharmaceutical; Generic equivalent or Oruvail, Approved December 1997
Synvisc, Synvisc-One (Hylan GF 20); Genzyme; For the treatment of pain associated with osteoarthritis of the knee, Approved August 1997
Tolmetin Sodium; Teva Pharmaceutical; Treatment for arthritis, Approved March 1997
Drugs Approved in 1996
Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP); Pharmacia & Upjohn; Treatment for rheumatoid arthritis, Approved October 1996
Lodine (etodolac); Wyeth; Treatment for rheumatoid arthritis, Approved July 1996
Naprelan (naproxen sodium); Elan Pharmaceuticals, Wyeth; Treatment for osteoarthritis and rheumatoid arthritis, Approved January 1996
